Promote a healthier life
for humankind through
advancements in science

Science-based

Benefit the patients with
high-quality medication as
we determined to innovate

Innovation-driven

Build a leading global
biopharmaceutical group
to serve more

Going Global

Fulfill social responsibilities
through accountable actions

Embrace Social
Responsibilities

Explore who we are

About us

Innovation is the core of our development strategy

Partnering

We are actively looking for synergistic partnerships

Walk into Hengrui

Est.

1970

New Molecular Entity drugs marketed in China

27

Other innovative drugs marketed in China

6

SH 600276

HK 1276

Est.

1970

Marketed Innovative Products in China

8

Partnered Innovative Product Launched

1

SH 600276

HK 1276

Pipeline

Our innovative pipeline covers the most of major therapeutic areas and continues to grow

Pipeline

Our innovative pipeline covers the most of major therapeutic areas and continues to grow

Investor

Enhance communication between our company and investors

Media

Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026

Media

Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

Media

Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury® (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer